Gilenya® Demonstrates Consistent Benefits..........

[MSUK]

Gilenya® Demonstrates Consistent Benefits In Reduction Of Relapses And Brain Volume Loss In Relapsing-Remitting MS

Data presented at the 65th annual meeting of the American Academy of Neurology (AAN) show Gilenya® (fingolimod), the first and only once-daily oral therapy reimbursed to treat highly active relapsing-remitting multiple sclerosis (RRMS), significantly and consistently reduced the rate of brain volume loss and reduced relapse rates compared to interferon beta-1a IM or placebo.

The new data add to the growing body of evidence for fingolimod regarding its early efficacy benefits and long-term safety profile..........Read More - http://www.ms-uk.org/index.cfm/gilenya